loading page

Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19
  • +3
  • qi Kong,
  • Zhiguang Xiang,
  • Yue Wu,
  • Yu Gu,
  • Jianguo Guo,
  • Xiuping Chen
qi Kong
Chinese Academy of Medical Sciences Institute of Laboratory Animal Sciences
Author Profile
Zhiguang Xiang
Chinese Academy of Medical Sciences Institute of Laboratory Animal Sciences
Author Profile
Yue Wu
Chinese Academy of Medical Sciences Institute of Laboratory Animal Sciences
Author Profile
Yu Gu
Chinese Academy of Medical Sciences Institute of Laboratory Animal Sciences
Author Profile
Jianguo Guo
Chinese Academy of Medical Sciences Institute of Laboratory Animal Sciences
Author Profile
Xiuping Chen
Qingdao University Medical College
Author Profile

Abstract

Background and Purpose: Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been used for anti-SARS-CoV-2 infection, anti-inflammation effect, and clear infection. PDL is one of the therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified. Experimental Approach: We used network pharmacology analysis, and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. WebGestalt (WEB-based Gene SeT AnaLysis Toolkit) was used for gene set enrichment analysis (GSEA) for functions and pathways enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform. Key Results: PDL may prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It may inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C Motif Chemokine Ligand 5 (CCL5), transforming growth factor-β1 (TGFβ1), and other proteins. PDL may moderate immune system to shorten the course of the disease, delay disease progression and reduce the mortality rate. Conclusion and Implications: We showed the molecular mechanism of PDL treatment for COVID-19. Based on previous studies, PDL was proven to be useful in the treatment of COVID-19 via different levels studies including clinical practice, animal experiments, cell testing, and network pharmacology.